Physician profile
David A Sanchez
NPI 1316162258
$12,235.60
in general payments reported to CMS, 2019-2025
37 companies · $2,445 in 2025
The $2,445 reported for 2025 was more than what 97% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,045 · 2020: $494 · 2021: $1,101 · 2022: $2,170 · 2023: $1,748 · 2024: $2,232 · 2025: $2,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,283 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125 · Education: $16.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,283.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124.88 |
| Education | $16.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,310.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,316.20 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $1,251.58 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $1,215.41 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $791.48 | 2019-2024 | Cuvitru, Hyqvia |
| Bayer Healthcare Pharmaceuticals INC. | $673.79 | 2023-2025 | |
| Corcept Therapeutics | $584.57 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $496.32 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $372.50 | 2022-2024 | Shingrix |
| Amarin Pharma, INC. | $317.77 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $290.26 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.92 | 2019-2024 | Spevigo |
| Sanofi-Aventis U.S. LLC | $266.48 | 2019-2023 | |
| Abbvie INC. | $210.52 | 2021-2024 | Vraylar |
| Sumitomo Pharma America, INC. | $195.68 | 2024-2025 | Gemtesa |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $183.85 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $151.69 | 2024-2025 | Voquezna |
| Botanix Sb INC | $150.00 | 2025 | Sofdra |
| Stryker Corporation | $149.97 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $146.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $136.70 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $134.88 | 2021 | |
| Astellas Pharma US INC | $117.93 | 2020 | |
| Daiichi Sankyo INC. | $112.40 | 2019 | |
| Abbott Laboratories | $78.03 | 2024-2025 | Freestyle Libre 3 |
| Pfizer INC. | $56.88 | 2023-2024 | |
| Almatica Pharma LLC | $37.36 | 2021 | |
| Recordati_rare_diseases_inc. | $34.48 | 2025 | Isturisa |
| Boston Scientific Corporation | $28.14 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $25.60 | 2023 | Dupixent |
| Electromed, INC. | $22.39 | 2022 | |
| Dexcom, INC. | $22.11 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $20.08 | 2020 | |
| Xeris Pharmaceuticals, INC. | $20.01 | 2024 | Gvoke Hypopen |
| Gilead Sciences, INC. | $15.01 | 2020 | |
| Cranial Technologies, INC | $14.55 | 2024 | Doc Band |
| Currax Pharmaceuticals LLC | $13.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.